Loomis, Sayles & Company
VIVO

Loomis, Sayles & Company’s Meridian Bioscience Inc VIVO Stock Holding History

Loomis, Sayles & Company’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,041
Closed -$18K – 774
2019
Q1 		$18K Buy
+1,041
New +$17.3K ﹤0.01% 672
2018
Q2 		– Sell
-1,419
Closed -$20K – 936
2018
Q1 		$20K Buy
1,419
+984
+226% +$14.6K ﹤0.01% 772
2017
Q4 		$6K Sell
435
-406
-48% -$5.94K ﹤0.01% 829
2017
Q3 		$12K Buy
841
+406
+93% +$5.8K ﹤0.01% 786
2017
Q2 		$7K Buy
+435
New +$6.27K ﹤0.01% 845

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company's VIVO Position: Q2 2019 in Review

Loomis, Sayles & Company sold out of Meridian Bioscience Inc (VIVO) in Q2 2019, closing a stake of 1,041 shares — an estimated $18K sold.

Loomis, Sayles & Company first reported a position in VIVO in Q2 2017 and held it in 5 quarters. The position peaked at $20K in Q1 2018. 173 funds tracked by Wall St. Rank hold VIVO as of Q2 2019.

  • Loomis, Sayles & Company reported no remaining Meridian Bioscience Inc position as of Q2 2019 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,041 Meridian Bioscience Inc shares in Q2 2019, an estimated $18K.
  • Loomis, Sayles & Company first reported a position in Meridian Bioscience Inc in Q2 2017 and held it in 5 quarters.
  • Loomis, Sayles & Company's Meridian Bioscience Inc position peaked at $20K in Q1 2018.
  • 173 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2019.

Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.